Bavarian Nordic (OTCMKTS:BVNRY) Posts Earnings Results

Key Points

• Bavarian Nordic reported quarterly earnings of $0.23 per share, with a net margin of 21.11% and a return on equity of 11.89%.
• The company's market capitalization stands at $2.91 billion and its price-to-earnings ratio is 15.38.
• Bavarian Nordic specializes in developing life-saving vaccines, including those for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) released its quarterly earnings data on Friday. The company reported $0.23 earnings per share for the quarter, Zacks reports. Bavarian Nordic had a net margin of 21.11% and a return on equity of 11.89%.

Bavarian Nordic Trading Down 0.4%

Bavarian Nordic stock opened at $12.3050 on Friday. Bavarian Nordic has a 1-year low of $6.5950 and a 1-year high of $14.11. The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of 15.38 and a beta of 1.36. The firm's fifty day moving average price is $10.44 and its two-hundred day moving average price is $8.84.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.